

Appl. No. 09/705,526

13. (Amended) A method of eye treatment, comprising:
subjecting the eye of a human patient to refractive surgery;
allowing the eye of the patient to recover; and
administering to the patient a formulation comprised of an alpha 1 antagonist wherein the formulation is a liquid formulation applied directly to the eye of the patient.

16. (Amended) An ophthalmic, night vision formulation, comprising:
a sterile aqueous carrier; and
a therapeutically effective amount of a pharmaceutically active compound comprising an alpha 1 antagonist capable of disrupting endogenous compounds which stimulate dilator muscles of a human eye.

17. (Amended) The ophthalmic formulation of claim 16, wherein the formulation further comprises tetrahydrazolene.

18. (Amended) The formulation of claim 16, wherein the alpha 1 antagonist is selected from the group consisting of a phenoxybenzamine and a phentolamine.

19. (Amended) The formulation of claim 16, wherein the alpha 1 antagonist is present in a concentration in a range of from about 0.01 milligrams per cubic centimeter of solvent to about 50 milligrams per cubic centimeter of solvent and wherein the solvent comprises an ophthalmic artificial tear solution.